Kimia Farma Tbk PT
IDX:KAEF
Kimia Farma Tbk PT
Research & Development
Kimia Farma Tbk PT
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Research & Development
-Rp22.6B
|
CAGR 3-Years
35%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-5%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Research & Development
-Rp727.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Research & Development
-Rp30.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Research & Development
-Rp24.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Research & Development
-Rp28.2B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kimia Farma Tbk PT
Glance View
PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.
See Also
What is Kimia Farma Tbk PT's Research & Development?
Research & Development
-22.6B
IDR
Based on the financial report for Sep 30, 2025, Kimia Farma Tbk PT's Research & Development amounts to -22.6B IDR.
What is Kimia Farma Tbk PT's Research & Development growth rate?
Research & Development CAGR 10Y
-5%
Over the last year, the Research & Development growth was 55%. The average annual Research & Development growth rates for Kimia Farma Tbk PT have been 35% over the past three years , -11% over the past five years , and -5% over the past ten years .
